Welcome to our dedicated page for Avepoint SEC filings (Ticker: AVPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AvePoint’s shift to a recurring-revenue SaaS model means critical numbers—ARR growth, net retention, cloud marketplace expansion—are buried deep in its regulatory reports. Browsing a 300-page annual filing just to confirm Microsoft partnership royalties can feel impossible. Investors, analysts, and even customers ask for “AvePoint SEC filings explained simply,” so they can track how data-governance subscriptions translate into cash flow. Miss a footnote and you might overlook deferred revenue tied to multi-year Microsoft 365 licenses.
Stock Titan’s AI reads every AvePoint quarterly earnings report 10-Q filing the moment it hits EDGAR, flags changes in deferred revenue, and renders the ratios in plain English. The same technology turns the AvePoint annual report 10-K simplified into a crisp overview of segment performance and customer-count trends. Sudden cloud outages or partnership updates? Our dashboard delivers AvePoint 8-K material events explained alongside redlined text, so you see exactly what changed. For governance watchers, we surface AvePoint proxy statement executive compensation tables with side-by-side year-over-year comparisons.
Curious about insider sentiment? Receive push alerts on AvePoint insider trading Form 4 transactions within seconds. Our system captures AvePoint Form 4 insider transactions real-time, tags each AvePoint executive stock transactions Form 4 entry, and links it back to the related disclosure. Interactive charts power AvePoint earnings report filing analysis, letting you compare ARR guidance against actual bookings. Whether you’re building a DCF or checking compliance exposure, understanding AvePoint SEC documents with AI means fewer surprises and faster, evidence-based decisions.
AvePoint, Inc. (AVPT) filing reports a proposed sale of 35,000 common shares through Rockefeller Financial with an aggregate market value of $543,633.74, with an approximate sale date of 09/23/2025. The shares were originally received as a restricted stock grant on 07/07/2022 and were granted as compensation. The issuer has 211,926,808 shares outstanding. The filer previously sold three blocks of 35,000 shares on 06/23/2025, 07/23/2025 and 08/25/2025, with gross proceeds shown for each transaction. The notice includes the standard representation regarding absence of undisclosed material information.
AvePoint director John Chi On Ho reported the sale of 650,000 shares of common stock on 09/18/2025 at $15.21 per share. The filing shows the shares were sold to provide initial liquidity for the company's secondary listing on the Singapore Exchange; no shares were sold on Nasdaq in connection with this transaction. After the sale, the reporting person is shown as beneficially owning 3,732,679 shares indirectly through Balmoral Blue Limited, subject to a disclaimer of full beneficial ownership.
The sale was executed under Rule 144 and the company's insider trading policies. The report is limited to this non-derivative equity transaction and explains the reporting person’s indirect ownership via Balmoral Blue Limited.
AvePoint Executive Chairman and Director Gong Xunkai reported a sale of 2,068,966 common shares on 09/18/2025 at $15.21 per share conducted in connection with AvePoint's secondary listing on the Singapore Exchange Securities Trading Limited (SGX-ST). The filing states the sale facilitated initial liquidity for the SGX-ST listing, was executed in accordance with Rule 144 and applicable insider trading policies, and that no shares were sold on NASDAQ. Following the transaction the reporting person beneficially owns 15,220,668 shares, comprised of shares held by affiliated LLCs and trusts for which he is trustee, with a disclaimer limiting admission of beneficial ownership.
AvePoint director and CEO Dr. Jiang Tianyi reported a sale of 2,068,966 common shares at $15.21 per share on 09/18/2025 to facilitate initial liquidity for the company's secondary listing on the Singapore Exchange (SGX-ST). The filing states the sale complied with Rule 144 and insider trading policies and that no shares were sold on NASDAQ. After the transaction Dr. Jiang is reported to beneficially own 13,841,853 shares indirectly through trusts and LLCs, with the filing listing specific affiliated entities and trusts that hold those shares.
Caci James, Chief Financial Officer and director of AvePoint, Inc. (AVPT), reported a sale of 216,000 shares of the issuer's common stock on 09/18/2025 at a price of $15.21 per share executed on the Singapore Exchange Securities Trading Limited (SGX-ST) to facilitate initial liquidity related to the company's SGX-ST secondary listing. The filing states the transaction complied with Rule 144 and the company's insider trading policies. Following the reported sale, the reporting person beneficially owns 213,030 shares, which include non-RSU common stock and both vested and unvested restricted stock units (RSUs) granted under the 2021 Equity Incentive Plan as previously disclosed.
AvePoint insider sale of 500,000 shares to support SGX secondary listing. Brian Michael Brown, who serves as Chief Legal Officer and a Director, sold 500,000 shares of AvePoint common stock on 09/18/2025 at $15.21 per share as part of the company’s secondary listing on the Singapore Exchange to facilitate initial liquidity. The filing states no shares were sold on NASDAQ and the transaction was executed in accordance with Rule 144 and company insider trading policies. After the sale the report shows 640,288 shares beneficially owned indirectly, held by the Brian M. Brown Revocable Trust.
AvePoint, Inc. (AVPT) Executive Chairman and Director Gong Xunkai reported a Form 4 disclosing a routine tax-withholding share disposition related to equity vesting. On 09/12/2025 the filing shows 4,025 shares of common stock were disposed of at a price of $15.61 per share to satisfy tax withholding obligations arising from the net settlement of vested restricted stock units (RSUs). After the transaction, the reporting person beneficially owned 770,202 shares, a total that includes both non-RSU common stock and vested and unvested RSUs previously reported. The Form 4 identifies Gong Xunkai as a Director, 10% owner and Executive Chairman. The filing states the withholding was an exempt transaction under Rule 16b-3 and not a discretionary sale by the reporting person.
Jiang Tianyi, who serves as AvePoint, Inc.'s Chief Executive Officer, Director and a reported 10% owner, reported a transaction on 09/12/2025 involving the company's common stock. The filing shows 2,914 shares were disposed of at a price of $15.61 per share. The Form 4 explains this disposition was an exempt net settlement where the issuer withheld shares to satisfy income tax withholding obligations related to vested restricted stock units (RSUs).
After the transaction, the reporting person is shown as beneficially owning 556,340 shares, which combines non-RSU common stock and aggregate vested and unvested RSUs previously disclosed. The form was signed by an attorney-in-fact on 09/16/2025.
Brian Michael Brown, Chief Legal Officer and director of AvePoint, Inc. (AVPT), reported a transaction on Form 4 showing a disposition of 5,010 shares on 09/12/2025. The filing states the transaction was an exempt withholding to satisfy tax obligations in connection with the net settlement of restricted stock units (RSUs) granted under the company’s 2021 Equity Incentive Plan, at an effective price of $15.61 per share.
After the withholding, the reporting person beneficially owned 1,140,288 shares, which includes both non‑RSU common stock and aggregate vested and unvested RSUs previously reported. The filing is signed and dated 09/16/2025.
AvePoint, Inc. (AVPT) Chief Financial Officer Caci James reported a tax-withholding disposition of company shares tied to RSU vesting. The Form 4 shows a disposition of 6,120 common shares on 09/12/2025 at a price of $15.61 per share, described as withholding to satisfy income tax obligations related to net settlement of restricted stock units. After the transaction the reporting person beneficially owns 668,493 shares, which includes both non-RSU common stock and aggregate vested and unvested RSUs held under previously disclosed vesting schedules. The filing is signed by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of Avepoint (AVPT)?
What is the market cap of Avepoint (AVPT)?
